DR. JOHN J DIGIOVANNA, MD
Dermatology at Democracy Blvd, Bethesda, MD

License number

Maryland MD9411

Personal information

See more information about JOHN J DIGIOVANNA at radaris.com

Name

Address

Phone

John Digiovanna

7930 Old Georgetown Rd, Bethesda, MD 20814

(301) 652-3244

John Digiovanna, age 73

8916 Burdette Rd, Bethesda, MD 20817

John J Digiovanna, age 73

8916 Burdette Rd, Bethesda, MD 20817

(301) 469-7243

John J Digiovanna, age 73

8908 Burdette Rd, Bethesda, MD 20817

(301) 469-7243

John J Digiovanna

7930 Old Georgetown Rd, Bethesda, MD 20814

(301) 652-3244

Professional information

See more information about JOHN J DIGIOVANNA at trustoria.com

Dr. John J Digiovanna, Bethesda MD - MD (Doctor of Medicine)

Specialties:

Dermatology

Address:

6302 Democracy Blvd, Bethesda 20817
(301) 530-8585 (Phone), (301) 530-3762 (Fax)

Certifications:

Dermatology, 1980

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
SUNY Upstate Medical University (Syracuse)
Graduated: 1976
Li Jewish Hospital Hillside
Graduated: 1977
University Miami
Graduated: 1980
National Institute Of Health
Graduated: 1984

John J Digiovanna, Bethesda MD

Specialties:

Dermatologist

Address:

6302 Democracy Blvd, Bethesda, MD 20817
6316 Democracy Blvd, Bethesda, MD 20817

Education:

State University of New York, Upstate Medical University - Doctor of Medicine
University of Miami Hospital - Residency - Dermatology

Board certifications:

American Board of Dermatology Certification in Dermatology

Use Of Synthetic Peptides To Disrupt The Cytoskeleton

US Patent:

5527773, Jun 18, 1996

Filed:

Aug 25, 1993

Appl. No.:

8/112784

Inventors:

Peter M. Steinert - Rockville MD
Robert D. Goldman - Wilmette IL
John J. DiGiovanna - Bethesda MD

Assignee:

United States of America - Washington DC

International Classification:

A61K 3810, A61K 3818

US Classification:

514 12

Abstract:

Synthetic peptides corresponding to different regions of the human keratin 1 chain can disassemble preformed keratin intermediate filaments or inhibit filament assembly both in vitro and in vivo. The disruption of keratin filaments may have therapeutic applications in the treatment of epithelial abnormalities.